Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06132256 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06132256 · ClinicalTrials.gov record · last posted 2026-03-27

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Name: MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — clinical trial record (NCT06132256)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorSyndax Pharmaceuticals

Started2023-12-11

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

Amendment record 16 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 16 times since 2023-11-09; most recent amendment 2026-03-25. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-25

Status change Recruiting→Active, Not Recruitingv16

2024-01-25

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT06132256
Lead Sponsor	Syndax Pharmaceuticals Collaborators: DevPro Biopharma
Conditions	Idiopathic Pulmonary Fibrosis
Enrollment	145 participants
Start Date	2023-12-11
Primary Completion	2026-09 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2026-03-27